NCT02150967 - A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Biotech Hunter

Enrollment

143

Participants

Timeline

Start Date

July 23, 2014

Primary Completion Date

March 1, 2021

Study Completion Date

February 7, 2022

Conditions

Advanced CholangiocarcinomaFGFR2 Gene Mutation

Interventions

DRUG

BGJ398 (infigratinib)

Capsule for oral use

Trial Locations (37)

1200

QED Investigative Site, Brussels

3000

QED Investigative Site, Leuven

8035

QED Investigative Site, Barcelona

8908

QED Investigative Site, Barcelona

10016

QED Investigative Site, New York

10029

QED Investigative Site, New York

10041

QED Investigative Site, Taipei

10065

QED Investigative Site, New York

10330

QED Investigative Site, Bangkok

10400

QED Investigative Site, Bangkok

20132

QED Investigative Site, Milan

28050

QED Investigative Site, Madrid

35053

QED Investigative Site, Zhunan

40002

QED Investigative Site, Khon Kaen

43221

QED Investigative Site, Columbus

48201

QED Investigative Site, Detroit

50937

QED Investigative Site, Cologne

60126

QED Investigative Site, Ancona

69120

QED Investigative Site, Heidelberg

85054

QED Investigative Site, Phoenix

90033

QED Investigative Site, Los Angeles

90095

QED Investigative Site, Los Angeles

94158

QED Investigative Site, San Francisco

119228

QED Investigative Site, Singapore

125367

QED Investigative Site, Moscow

169610

QED Investigative Site, Singapore

404133

QED Investigative Site, Volzhskiy

02114

QED Investigative Site, Boston

77030-4009

QED Investigative Site, Houston

Unknown

QED Investigative Site, Tübingen

00168

QED Investigative Site, Roma

03080

QED Investigative Site, Seoul

06351

QED Investigative Site, Seoul

CH63 4JY

QED Investigative Site, Bebington

B15 2TH

QED Investigative Site, Birmingham

M20 4BX

QED Investigative Site, Manchester

NG5 1PB

QED Investigative Site, Nottingham